Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer

1. Martín, M.
2. Makhson, A.
3. Gligorov, J.
4. Lichinitser, M.
5. Lluch, A.
6. Semiglazov, V.
7. Scotto, N.
8. Mitchell, L.
9. Tjulandin, S.